Developing Effective Alzheimer’s Disease Therapies: Clinical Experience and Future Directions
Open accessThe DOI matches its Crossref record; 101 of the 102 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease (AD) clinical trials, focused on disease modifying drugs and conducted in patients with mild to moderate AD, as well as prodromal (early) AD, have failed to reach efficacy endpoints in improving cognitive function in most cases to date or have been terminated due to adverse events. Drugs that have reached clinical stage were reviewed using web resources (such as clinicaltrials.gov, alzforum.org, company press releases, and peer reviewed literature) to identify late stage (Phase II and Phase III) efficacy clinical trials and summarize reasons for their failure. For each drug, only the latest clinical trials and ongoing trials that aimed at improving cognitive function were included in the analysis. Here we highlight the potential reasons that have hindered clinical success, including clinical trial design and choice of outcome measures, heterogeneity of patient populations, difficulties in diagnosing and staging the disease, drug design, mechanism of action, and toxicity related to the long-term use. We review and suggest approaches for AD clinical trial design aimed at improving our ability to identify novel therapies for this devastating disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of phase II and III trials center around neurotransmitter receptors and Aβ mechanisms, while tau and inflammation drugs are more prominent in phase II, often featuring repurposed compounds.”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [436]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thus, drug development landscape for combination therapy is becoming increasingly crowded with both symptomatic and disease-modifying applications.51”
From From combinations to multitarget-directed ligands: A continuum in Alzheimer’s disease polypharmacology (2021) · cites this paper as [51]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The major mechanisms of action center around: 1) neurotransmitter receptors, including AChE, NMDA receptor, 5-hydroxytryptamine receptor, nicotinic α7 receptor, and adrenoceptor; 2) Aβ, including the reduction of Aβ production (such as γ-secretase inhibitors and modulators, BACE1 inhibitors, and α-secretase activators), prevention of Aβ aggregation, and enhancing Aβ clearance (vaccines and ant”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [436]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657 · cited 1×
“The use of CSF biomarkers in research and clinical trials, in addition to clinical criteria is detailed in the revised diagnostic criteria of AD [24, 105], suggesting the use of CSF biomarkers in differentiating between AD and other types of dementia.”
MethodThe Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152 · cited 3×
“The use of CSF biomarkers in research and clinical trials, in addition to clinical criteria is detailed in the revised diagnostic criteria of AD [24, 105], suggesting the use of CSF biomarkers in differentiating between AD and other types of dementia.”
BackgroundMethodNeuroinflammation in Alzheimer's disease
Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70016-5 · Cited by 6,226 · cited 1×
“Similarly, stage-dependent efficacy of anti-inflammatory agents, suggests that these treatments may be useful early in AD [90, 103].”
BackgroundAlzheimer's Disease: Genes, Proteins, and Therapy
Selkoe, D. J. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.741 · Cited by 6,063
Complement and microglia mediate early synapse loss in Alzheimer mouse models
Hong, S., Beja-Glasser, V. F., Nfonoyim, B. M., Frouin, A., Li, S., Ramakrishnan, S., Merry, K. M., Shi, Q., Rosenthal, A., Barres, B. A., et al. (2016) · Science · doi:10.1126/science.aad8373 · Cited by 3,343
TREM2 Variants in Alzheimer's Disease
Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J. S. K., Younkin, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211851 · Cited by 3,020
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2013) · Focus · doi:10.1176/appi.focus.11.1.96 · Cited by 2,621
Variant of TREM2 Associated with the Risk of Alzheimer's Disease
Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P. V., Snaedal, J., Bjornsson, S., Huttenlocher, J., Levey, A. I., Lah, J. J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211103 · Cited by 2,558 · cited 1×
“Further, new understanding of the multiple roles of microglia and factors that affect their function in the progression of AD [10, 11, 35, 56, 57], has potential to open vastly new therapeutic options and targets.”
Background
Research works printed but not linked: 7
- Lilly Press Release, Update on Phase 3 Clini- cal Trials of Lanabecestat for Alzheimer's Disease. https://investor.lilly.com/node/39051/pdf, Posted June 12, 2018, Accessed February13, 2019.
- Merck Press Release, Merck Announces EPOCH Study of Verubecestat for the Treatment of People with Mild to Moderate Alzheimer's Disease to Stop for Lack of Efficacy, https://investors.merck.com/news/press- release-details/2017/Merck-Announces-EPOCH-Study- of-Verubecestat-for-the-Treatment-of-People-with-Mild- to-Moderate-Alzheimers-Disease-to-Stop-for-Lack-of- Efficacy/, Posted February 14, 2017, Accessed February 13, 2019.
- Biogen Press Release, Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of Aducanumab in Alzheimer's Disease, http://investors.biogen.com/news- releases/news-release-details/biogen-and-eisai- discontinue-phase-3-engage-and-emerge-trials, Posted March 21, 2019, Accessed March 29, 2019.
- Biogen Press Release, Eisai and Biogen Announce Posi- tive Topline Results of the Final Analysis for BAN2401 at 18 Months, http://investors.biogen.com/news- releases/news-release-details/eisai-and-biogen- announce-positive-topline-results-final, Posted July 5, 2018, Accessed February 13, 2019.
- Roche Press Release, Roche to discontinue Phase III CREAD 1 and 2 clinical studies of crenezumab in early Alzheimer's disease (AD) -other company programmes in AD continue, https://www.roche.com/media/releases/med-cor-2019- 01-30.htm, Posted January 30, 2019, Accessed March 29, 2019.
- Lilly Press Release, Lilly Announces Top-Line Results of Solanezumab Phase 3 Clinical Trial, https://investor.lilly.com/static-files/9117f89a-0f6a- 4dd8-a73e-97c108cf613d, Posted November 23, 2016, Accessed February 13, 2019.
- Lilly Press Release, Lilly Voluntarily Terminates Phase II Study for LY2886721, a Beta Secretase Inhibitor, Being Investigated as a Treatment for Alzheimer's Disease, https://investor.lilly.com/news-releases/news- release-details/lilly-voluntarily-terminates-phase-ii- study-ly2886721-beta, Posted June 13, 2016, Accessed February 13, 2019.
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
Current understanding of metal ions in the pathogenesis of Alzheimer’s disease
Wang, L., Yin, Y.-L., Liu, X.-Z., Shen, P., Zheng, Y.-G., Lan, X.-R., Lu, C.-B., & Wang, J.-Z. (2020) · Translational Neurodegeneration · doi:10.1186/s40035-020-00189-z · Cited by 454
“Furthermore, aggregation of Aβ could form oligomers and plaques, and the oligomers are recognized as the more toxic form of Aβ [3, 4].”
BackgroundInflammatory Processes in Alzheimer’s Disease—Pathomechanism, Diagnosis and Treatment: A Review
Twarowski, B., & Herbet, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076518 · Cited by 412
“From a clinical point of view, the genetic diagnostics of inflammation that develops in the course of Alzheimer’s disease is also important [159].”
Jeremic, D., Jiménez-Díaz, L., & Navarro-López, J. D. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101496 · Cited by 306
“Similar situation was with Octagam® (Phase II, completed, MCI/mild to moderate AD), where only transient improvement of patients was observed, without significant efficacy of the treatment (Elmaleh et al., 2019).”
MethodResultChallenges and hopes for Alzheimer’s disease
Tatulian, S. A. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.01.016 · Cited by 291
Chen, L.-L., Fan, Y.-G., Zhao, L.-X., Zhang, Q., & Wang, Z.-Y. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.106301 · Cited by 200
Albertini, C., Salerno, A., de Sena Murteira Pinheiro, P., & Bolognesi, M. L. (2021) · Medicinal Research Reviews · doi:10.1002/med.21699 · Cited by 179
“Thus, drug development landscape for combination therapy is becoming increasingly crowded with both symptomatic and disease‐modifying applications.(51) Examples of current trials are shared, with a focus on the polypharmacological rationale for their development.”
BackgroundA second X chromosome contributes to resilience in a mouse model of Alzheimer’s disease
Davis, E. J., Broestl, L., Abdulai-Saiku, S., Worden, K., Bonham, L. W., Miñones-Moyano, E., Moreno, A. J., Wang, D., Chang, K., Williams, G., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz5677 · Cited by 176
“The burdens of the disease combined with failed clinical trials (3) warrant a deeper understanding of the heterogeneous nature of AD, with the goal of developing better therapies.”
An epoxide hydrolase inhibitor reduces neuroinflammation in a mouse model of Alzheimer’s disease
Ghosh, A., Comerota, M. M., Wan, D., Chen, F., Propson, N. E., Hwang, S. H., Hammock, B. D., & Zheng, H. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abb1206 · Cited by 136
Liu, P., Zhang, T., Chen, Q., Li, C., Chu, Y., Guo, Q., Zhang, Y., Zhou, W., Chen, H., Zhou, Z., et al. (2021) · Advanced Materials · doi:10.1002/adma.202100746 · Cited by 135
Tang, J., Huang, L.-F., Deng, J., Wang, Y., Guo, C., Peng, X.-N., Liu, Z., & Gao, J. (2022) · Redox Biology · doi:10.1016/j.redox.2022.102229 · Cited by 135
“However, numerous clinical trials were successively terminated [2].”
BackgroundAPOE-amyloid interaction: Therapeutic targets
Wisniewski, T., & Drummond, E. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104784 · Cited by 131
Burns, D. K., Alexander, R. C., Welsh-Bohmer, K. A., Culp, M., Chiang, C., O’Neil, J., Evans, R. M., Harrigan, P., Plassman, B. L., Burke, J. R., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00043-0 · Cited by 130
Iraji, A., Khoshneviszadeh, M., Firuzi, O., Khoshneviszadeh, M., & Edraki, N. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.103649 · Cited by 110
Moussa, N., & Dayoub, N. (2023) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2023.101729 · Cited by 102
“For example, treatment with ibuprofen at 400 mg had no significant cognitive benefit (Elmaleh et al. 2019), and naproxen at a dose of 220 mg was not effective in preventing the progression of pre-symptomatic AD (Benito-León et al.”
Astrocytic propagation of Tau in the context of Alzheimer's disease
Fleeman, R. M., & Proctor, E. A. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.645233 · Cited by 75
“These strategies have targeted what are known as the hallmarks of AD, amyloid-β (Aβ) plaques and hyperphosphorylated microtubule-associated protein tau (MAPT, or tau) aggregates (Franco and Cedazo-Minguez, 2014; Tai et al., 2015; Elmaleh et al., 2019; Tzioras et al., 2019), but a mechanistic understanding of how the p…”
BackgroundToll-like receptors in Alzheimer's disease
Momtazmanesh, S., Perry, G., & Rezaei, N. (2020) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2020.577362 · Cited by 69
Rui, W., Xiao, H., Fan, Y., Ma, Z., Xiao, M., Li, S., & Shi, J. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02329-2 · Cited by 97
“Although many pharmaceutical companies have developed drugs to alleviate the symptoms of Aβ accumulation, most of them have failed in clinical settings [2, 3].”
BackgroundMechanisms of Intranasal Deferoxamine in Neurodegenerative and Neurovascular Disease
Kosyakovsky, J., Fine, J. M., Frey, W. H., & Hanson, L. R. (2021) · Pharmaceuticals · doi:10.3390/ph14020095 · Cited by 67
Si, G., & Álvarez, A. (2020) · Medicinal Research Reviews · doi:10.1002/med.21722 · Cited by 65
“other therapeutic agents have been investigated for the symptomatic treatment or disease modification and failed to show clinical efficacy, including antiamyloid and antitau therapies, neurotrophic factors, anti‐inflammatory drugs, antioxidative products, and several other compounds targeting excitotoxicity and an arr…”
BackgroundResultSectoral segmentation of retinal amyloid imaging in subjects with cognitive decline
Dumitrascu, O. M., Lyden, P. D., Torbati, T., Sheyn, J., Sherzai, A. Z., Sherzai, D., Sherman, D. S., Rosenberry, R., Cheng, S. C., Johnson, K., et al. (2020) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12109 · Cited by 68
“Male (M) M (4) M (9) M (3) M (6) M (10)”
Neuroinflammation in pathogenesis of Alzheimer’s disease: Phytochemicals as potential therapeutics
Vaiserman, A., Koliada, A., & Lushchak, O. (2020) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2020.111259 · Cited by 57
Zhao, L., Meng, F., Li, Y., Liu, S., Xu, M., Chu, F., Li, C., Yang, X., & Luo, L. (2023) · Advanced Materials · doi:10.1002/adma.202210879 · Cited by 55
Pre‐diagnostic cognitive and functional impairment in multiple sporadic neurodegenerative diseases
Swaddiwudhipong, N., Whiteside, D. J., Hezemans, F. H., Street, D., Rowe, J. B., & Rittman, T. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12802 · Cited by 48
“However, treatment trials are typically conducted after symptoms have emerged, which may be too late in the disease process to alter its course [2, 3].”
BackgroundThe Functions and Phenotypes of Microglia in Alzheimer’s Disease
Fujikawa, R., & Tsuda, M. (2023) · Cells · doi:10.3390/cells12081207 · Cited by 47
“Although aggregation of amyloid-β (Aβ) and tau proteins may play crucial roles in the progression of AD, candidate drugs targeting Aβ or tau have failed to reach efficacy clinical endpoints for improving cognitive function [4].”
BackgroundChaudhari, V., Bagwe‐Parab, S., Buttar, H. S., Gupta, S., Vora, A., & Kaur, G. (2023) · Neurotoxicity Research · doi:10.1007/s12640-023-00634-7 · Cited by 49
“Furthermore, Aβ aggregation may result in the formation of oligomers and plaques, with the oligomers being the more toxic form of Aβ (Dubois et al. 2016; Elmaleh et al. 2019).”
BackgroundSlater, C. L., & Wang, Q. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.397 · Cited by 50
Borsom, E. M., Conn, K. A., Keefe, C. R., Herman, C., Orsini, G. M., Hirsch, A. H., Avila, M. P., Testo, G., Jaramillo, S. A., Bolyen, E. K., et al. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.03458-22 · Cited by 47
“Currently, the main targets of AD therapies are neurotransmitter receptors, secretase inhibitors, modulation of amyloidosis and tauopathy, and immunotherapy (29).”
BackgroundPatel, A. G., Nehete, P. N., Krivoshik, S. R., Pei, X., Cho, E. L., Nehete, B. P., Ramani, M. D., Shao, Y., Williams, L. E., Wisniewski, T., et al. (2021) · Brain · doi:10.1093/brain/awab129 · Cited by 44
Corsetti, V., Borreca, A., Latina, V., Giacovazzo, G., Pignataro, A., Krashia, P., Natale, F., Cocco, S., Rinaudo, M., Malerba, F., et al. (2020) · Brain Communications · doi:10.1093/braincomms/fcaa039 · Cited by 42
“…of unwanted consequences due to the ‘loss of function’ of normal protein—in the cure of human, chronic neurodegenerative tauopathies which are sometimes expected to require long-term treatments with multiple and high-dose administrations of drugs (Kontsekova et al. , 2014; Elmaleh et al. , 2019).”
InfluentialNeurotechnological Approaches to the Diagnosis and Treatment of Alzheimer’s Disease
Ning, S., Jorfi, M., Patel, S. R., Kim, D. Y., & Tanzi, R. E. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.854992 · Cited by 48
Self-citationCorreia, S. S., Iyengar, R. R., Germano, P., Tang, K., Bernier, S. G., Schwartzkopf, C. D., Tobin, J. V., Lee, T. W.-H., Liu, G., Jacobson, S., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.656561 · Cited by 44
“In light of recent high-profile failures in Alzheimer’s disease (AD) clinical trials (Elmaleh et al., 2019), approaches addressing the broader aspects of neurodegenerative pathologies such as neuroinflammation, synaptic and neuronal dysfunction, and cerebrovascular dysregulation may provide a path forward for new ther…”
BackgroundRecent progress of nanomedicine in the treatment of Alzheimer’s disease
Hu, L., Tao, Y., Jiang, Y., & Qin, F. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1228679 · Cited by 52
Neuroinflammation of Microglial Regulation in Alzheimer’s Disease: Therapeutic Approaches
Chen, H., Zeng, Y., Wang, D., Li, Y., Xing, J., Zeng, Y., Liu, Z., Zhou, X., & Fan, H. J. (2024) · Molecules · doi:10.3390/molecules29071478 · Cited by 46
New insights in drug development for Alzheimer's disease based on microglia function
Qiao, O., Ji, H., Zhang, Y., Zhang, X., Zhang, X., Liu, N., Huang, L., Liu, C., & Gao, W. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111703 · Cited by 35
Zhao, L., Duan, Z., Wang, Y., Wang, M., Liu, Y., Wang, X., & Li, H. (2020) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2020.113640 · Cited by 37
peng, Y., Chi, R., Liu, G., Tian, W., Zhang, J., & Zhang, R. (2022) · Neural Plasticity · doi:10.1155/2022/1500710 · Cited by 39
“The existing theories include Aβ deposition, excessive tau protein phosphorylation, free radical damage, choline deficiency, reactive synapse loss, and neurodegeneration [5, 6].”
BackgroundAbderrezag, N., Bragagnolo, F. S., Louaer, O., Méniai, A.-H., Cifuentes, A., Ibáñez, E., & Mendiola, J. A. (2024) · The Journal of Supercritical Fluids · doi:10.1016/j.supflu.2024.106211 · Cited by 35
“Most drugs currently approved for mid-to-moderate AD therapy are acetylcholinesterase (AChE) inhibitors, which improve learning and memory for AD patients by increasing the concentration of acetylcholine (ACh) [4].”
Bac, B., Hicheri, C., Weiss, C., Buell, A., Vilcek, N., Späni, C. B., Geula, C., Savas, J. N., & Disterhoft, J. F. (2022) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2022.12.015 · Cited by 31
Molecular Pathogenesis and Interventional Strategies for Alzheimer’s Disease: Promises and Pitfalls
Bhute, S., Sarmah, D., Datta, A., Rane, P., Shard, A., Goswami, A., Borah, A., Kalia, K., Dave, K. R., & Bhattacharya, P. (2020) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.9b00104 · Cited by 34
A comprehensive analysis of APOE genotype effects on human brain structure in the UK Biobank
Heise, V., Offer, A. R., Whiteley, W. N., Mackay, C. E., Armitage, J., & Parish, S. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-02848-5 · Cited by 37
“Therefore, changes in brain structure in healthy adults carrying APOE ε4 might be MRI biomarkers of pre-symptomatic AD that could identify potential participants for clinical trials of AD prevention or treatment before the onset of clinical symptoms, at which point interventions might be more effective [6].”
BackgroundHeuer, S. E., Neuner, S. M., Hadad, N., O'Connell, K. M. S., Williams, R. W., Philip, V. M., Gaiteri, C., & Kaczorowski, C. C. (2020) · Learning & Memory · doi:10.1101/lm.051839.120 · Cited by 29
Xu, L., Pan, C., Wu, X., Song, J., Meng, P., Li, L., Wang, L., Zhang, Z., & Zhang, Z.-Y. (2021) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2021.03.013 · Cited by 30
Cashew Nut Shell Liquid (CNSL) as a Source of Drugs for Alzheimer’s Disease
Uliassi, E., de Oliveira, A. S., Nascente, L. D. C., Romeiro, L. A. S., & Bolognesi, M. L. (2021) · Molecules · doi:10.3390/molecules26185441 · Cited by 36
“All controversy aside, the fact that it is the first new drug approved for AD since 2003, demonstrates that the development of new, effective drugs suffers an unsustainably high failure rate [3].”
BackgroundChandupatla, R., Flatley, A., Feederle, R., Mandelkow, E., & Kaniyappan, S. (2020) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12097 · Cited by 29
“2B10 and IgG control antibodies were taken up by cells and localized as punctate structures (images 2, 5).”
Molina‐Martínez, P., Corpas, R., García-Lara, E., Cosín‐Tomás, M., Cristòfol, R. M., Kaliman, P., Solà, C., Molinuevo, J. L., Sánchez‐Valle, R., Antonell, A., et al. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.622360 · Cited by 26
Thomas, A. J., Hamilton, C. A., Donaghy, P. C., Martin-Ruiz, C. M., Morris, C. M., Barnett, N., Olsen, K., Taylor, J., & O'Brien, J. T. (2020) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.5365 · Cited by 26
“However, there are no disease modifying treatments available for either disease, with a large number of trials having failed to demonstrate benefits.(29,30) Identification of new therapies for these devastating diseases is a major priority and targeting neuroinflammation is an attractive alternative therapeutic approa…”
BackgroundLimiting RyR2 open time prevents Alzheimer's disease‐related deficits in the 3xTG‐AD mouse model
Liu, Y., Yao, J., Song, Z., Guo, W., Sun, B., Wei, J., Estillore, J. P., Back, T. G., & Chen, S. R. W. (2021) · Journal of Neuroscience Research · doi:10.1002/jnr.24936 · Cited by 25
“Over the past several decades, tremendous resources and efforts have been spent on developing effective treatments for AD (Clement et al., 2020; Corbett et al., 2012; Elmaleh et al., 2019).”
BackgroundTrujillo‐Estrada, L., Vanderklish, P. W., Nguyen, M. M. T., Kuang, R. R., Nguyen, C., Huynh, E., da Cunha, C., Javonillo, D. I., Forner, S., Martini, A. C., et al. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01143-1 · Cited by 22
Liu, C., Zhang, L., Li, Y., Li, M., Han, H., & Wang, K. (2023) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x2350026x · Cited by 22
Chepisheva, M. (2023) · PeerJ · doi:10.7717/peerj.15040 · Cited by 31
“On the other hand, combined treatment strategies and multifaceted approaches show more promise (Elmaleh et al., 2019; Hou et al., 2019; Yu, Sporns & Saykin, 2021; Whitson et al., 2022).”
BackgroundZhu, M., Zhang, Y., Zhang, C., Chen, L., & Kuang, Y. (2023) · Journal of Biomaterials Applications · doi:10.1177/08853282231182765 · Cited by 22
“Due to the complexity of the etiology of AD, as yet, there is no effective methods or drugs to cure the disease in clinic.(3,4) Developing new diagnosis and treatment methods for AD is a huge challenge.”
Enhancing α-secretase Processing for Alzheimer’s Disease—A View on SFRP1
Tang, B. L. (2020) · Brain Sciences · doi:10.3390/brainsci10020122 · Cited by 23
Lynx1 prototoxins: critical accessory proteins of neuronal nicotinic acetylcholine receptors
Miwa, J. M. (2020) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2020.09.016 · Cited by 24
“Clinical improvements associated with this treatment, however, are limited [3].”
BackgroundKuroda, E., Takata, K., Nishimura, K., Oka, H., Sueyoshi, M., Aitani, M., Kouda, A., Satake, S., Shima, C., Toda, Y., et al. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190974 · Cited by 20
“Nonetheless, development of antibodies and chemicals targeting A (cid:2) , tau, and inflammation are ongoing [38].”
Effect of memantine, an anti-Alzheimer’s drug, on rodent microglial cells in vitro
Murakawa‐Hirachi, T., Mizoguchi, Y., Ohgidani, M., Haraguchi, Y., & Monji, A. (2021) · Scientific Reports · doi:10.1038/s41598-021-85625-4 · Cited by 20
Kapadia, A., Sharma, K. K., Maurya, I. K., Singh, V., Khullar, M., & Jain, R. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.113126 · Cited by 21
He, L., Wang, X., Zhao, J., & Lin, Z. (2022) · Journal of Functional Foods · doi:10.1016/j.jff.2022.105385 · Cited by 18
Gao, J., Wang, L., Zhao, C., Wu, Y., Lu, Z., Gu, Y., Ba, Z., Wang, X., Wang, J., & Xu, Y. (2021) · Journal of Leukocyte Biology · doi:10.1002/jlb.3ma0821-639rr · Cited by 19
Nehete, P. N., Williams, L. E., Chitta, S., Nehete, B. P., Patel, A. G., Ramani, M. D., Wısnıewskı, T., & Scholtzova, H. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00036 · Cited by 19
Identifying healthy individuals with Alzheimer’s disease neuroimaging phenotypes in the UK Biobank
Azevedo, T., Bethlehem, R. A. I., Whiteside, D. J., Swaddiwudhipong, N., Rowe, J. B., Lió, P., Rittman, T., Initiative, T. A. D. N., Silbert, L. C., Lind, B., et al. (2023) · Communications Medicine · doi:10.1038/s43856-023-00313-w · Cited by 20
“A critical task in dementia research is to identify disease at the earliest possible time point, permitting early intervention with lifestyle change 1 or disease-modifying therapies 2 at a time when the disease process could potentially be reversed or halted, and quality of life remains high.”
Yu, Y., He, S.-Y., Kong, L., Shi, N.-N., Liu, Y., Zang, J., Guo, R., Zhang, L., Li, X., & Li, X. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.104794 · Cited by 19
Ataei, B., Hokmabadi, M., Asadi, S., Asadifard, E., Zarch, S. M. A., Najafi, S., & Bagheri‐Mohammadi, S. (2024) · Gene · doi:10.1016/j.gene.2024.148368 · Cited by 21
Potential new therapeutic target for Alzheimer's disease: Glucagon‐like peptide‐1
Liu, X., Zhang, N., Zhang, S., & Xu, P. (2021) · European Journal of Neuroscience · doi:10.1111/ejn.15502 · Cited by 17
Herd, P., & Sicinski, K. (2021) · SSM - Population Health · doi:10.1016/j.ssmph.2021.100960 · Cited by 15
“Yet, while there have been significant scientific breakthroughs in research, we have yet to develop effective clinical treatments that preserve cognitive functioning in later life (Elmaleh et al., 2019).”
BackgroundAmyloid-beta Targeted Therapeutic Approaches for Alzheimer’s Disease: Long Road Ahead
Dai, Y., Lei, C., Zhang, Z., Qi, Y., Lao, K., & Gou, X. (2022) · Current Drug Targets · doi:10.2174/1389450123666220421124030 · Cited by 16
Plasma Exchange in Alzheimer's Disease
Rohrer, L., Yünce, M., Montine, T. J., & Shan, H. (2022) · Transfusion Medicine Reviews · doi:10.1016/j.tmrv.2022.09.005 · Cited by 15
Komura, T., Aoki, M., Kotoura, S., & Nishikawa, Y. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113769 · Cited by 17
Topalis, V., Voros, C., & Ziaka, M. (2025) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/08919887251361578 · Cited by 16
Chen, Z., Liu, S., Zhou, H., Wang, M., Pei, S., Wang, R., & Liu, Z. (2023) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2023.115930 · Cited by 12
Palko, S. I., Benoit, M., Yao, A. Y., Mohan, R., & Yan, R. (2024) · Glia · doi:10.1002/glia.24514 · Cited by 15
“Cognitive tests, brain PET scans, and various biomarkers such as A β levels are currently aiding in earlier diagnosis of AD (Elmaleh et al., 2019; Márquez & Yassa, 2019; West et al., 2021; Zetterberg & Blennow, 2021).”
MethodPrediction of cognitive conversion within the Alzheimer’s disease continuum using deep learning
Yang, S., Zhang, X., Du, X., Yan, P., Zhang, J., Wang, W., Wang, J., Zhang, L., Sun, H., Liu, Y., et al. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01686-x · Cited by 14
Pasieka, A., Panek, D., Zaręba, P., Sługocka, E., Gucwa, N., Espargaró, A., Latacz, G., Khan, N., Bucki, A., Sabaté, R., et al. (2023) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2023.117333 · Cited by 12
Aβ Oligomer Dissociation Is Catalyzed by Fibril Surfaces
Dear, A. J., Thacker, D., Wennmalm, S., Ortigosa-Pascual, L., Andrzejewska, E. A., Meisl, G., Linse, S. S., & Knowles, T. P. J. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00127 · Cited by 17
Mitochondria-targeting by small molecules against Alzheimer's disease: A mechanistic perspective
Pal, C. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2024.167617 · Cited by 14
Sadleir, K. R., Popović, J., Khatri, A. W., & Vassar, R. J. (2022) · PLoS ONE · doi:10.1371/journal.pone.0263332 · Cited by 12
Falkenstein, M., Reiner‐Link, D., Živković, A., Gering, I., Willbold, D., & Stark, H. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116462 · Cited by 13
Barthelson, K., Pederson, S., Newman, M., Jiang, H., & Lardelli, M. T. (2021) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-200279 · Cited by 13
“However, all compounds to date show little or no effect on cognitive symptoms (reviewed in [4, 5]).”
A novel framework of MOPSO-GDM in recognition of Alzheimer's EEG-based functional network
Wang, R., Wang, H., Shi, L., Han, C., He, Q., Che, Y., & Li, L. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1160534 · Cited by 11
“, 2020, 2022), which has been shown in past studies that (in awake, resting conditions) a pronounced amplitude decrease of α band (Wang et al., 2015a,b; Elmaleh et al., 2019) and a global “slowing” of the background EEG rhythms, with the increase of δ and θ frequencies, the appearance of background EEG rhythms shows a…”
BackgroundLi, P., He, Y., Yang, Q., Guo, H., Li, N., & Zhang, D. (2023) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.22-105 · Cited by 11
Chakraborty, S., Vishwas, S., Harish, V., Gupta, G., Paudel, K. R., Dhanasekaran, M., Goh, B. H., Zacconi, F. C. M., Pinto, T. D. J. A., Kumbhar, P., et al. (2024) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2024.2414768 · Cited by 12
“The traditional drug discovery for AD has faced several challenges in numerous clinical trials failing to produce an effective treatment [29].”
Insulin signaling as a therapeutic target in Alzheimer’s disease: Efficacy of apomorphine
Ohyagi, Y., & Takei, S. (2020) · Neurology and Clinical Neuroscience · doi:10.1111/ncn3.12369 · Cited by 10
Schechter, G., Azad, G. K., Rao, R. V., McKeany, A. M., Matulaitis, M., Kalos, D. M., & Kennedy, B. K. (2020) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-200185 · Cited by 10
“dollars, without significant success [1, 2].”
Altendorf, T., Gering, I., Santiago‐Schübel, B., Saisan, S. A., Tamgüney, G., Tusche, M., Honold, D., Schemmert, S., Hoyer, W., Mohrlüder, J., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032161 · Cited by 8
“Many therapeutic approaches were developed to target Aβ pathology but did not yield positive results in clinical trials [8].”
Versaci, M., & Foresta, F. L. (2024) · Signals · doi:10.3390/signals5020018 · Cited by 12
“Early diagnosis of AD is essential for optimal management of the disease, but is hampered by the limited effectiveness of current therapies in slowing its progression [20], underlining the urgent need to develop more effective treatments [21–23].”
BackgroundQuan, Q., Ma, X., Feng, J., Li, W., & Li, X. (2025) · Neuropeptides · doi:10.1016/j.npep.2025.102514 · Cited by 9
Synthesis of Novel Pyrazolo[3,4-b]pyridines with Affinity for β-Amyloid Plaques
Vidali, V. P., Nigianni, G., Athanassopoulou, G. D., Canko, A., Mavroidi, B., Matiadis, D., Pelecanou, M., & Sagnou, M. (2022) · Molbank · doi:10.3390/m1343 · Cited by 9
“Etazolate (Figure 2) is the only pyrazolo[3,4-b]pyridine clinically investigated for its efficacy as an anti-Alzheimer acting agent, as an α-secretase inhibitor for mild to moderate AD [31].”
BackgroundR-carvedilol, a potential new therapy for Alzheimer’s disease
Yao, J., & Chen, S. R. W. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1062495 · Cited by 11
“Over the past three decades, scientists across the world have made immense efforts to comprehend the pathogenesis of AD and develop effective AD treatments (Corbett et al., 2012; Elmaleh et al., 2019; Clement et al., 2020).”
BackgroundTargeting Calpain-2 for Alzheimer’s Disease Treatment
Arnsten, A. F. T., & Baudry, M. (2023) · Medical Research Archives · doi:10.18103/mra.v11i2.3487 · Cited by 7
Li, Y., Zhang, X., Zhao, H., Wang, Y., Zhang, D., Wang, X., Dong, R., Yan, X., Wu, J., Sui, Y., et al. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00149 · Cited by 6
Goldstein, M. R., & Cheslock, M. (2021) · Medical Hypotheses · doi:10.1016/j.mehy.2021.110645 · Cited by 8
Directional DBS of the Fornix in Alzheimer’s Disease Achieves Long-Term Benefits: A Case Report
Barcia, J. A., Viloria, M. A., Yubero, R., Sánchez-Sánchez-Rojas, L., Picado, A. L., Strange, B. A., Cabrera, M., Canuet, L., Gil, P., & Nombela, C. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.809972 · Cited by 8
Wang, Y., Cao, Y., Huang, H., Xue, Y., Chen, S., & Gao, X. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.109863 · Cited by 6
Li, A., Xue, C., Wu, R., Wu, W. D., Zhao, J., & Qiang, Y. (2024) · International Journal of Human-Computer Interaction · doi:10.1080/10447318.2024.2327179 · Cited by 8
“…approaches targeting AD, such as enzyme inhibition involved in amyloid-b generation and the use of antibodies to clear amyloid-b from the brain (Elmaleh et al., 2019; Karran & De Strooper, 2022), there still exists no disease-halting drugs to completely cure dementia or significantly alter its…”
Ghosh, A., Comerota, M. M., Wan, D., Chen, F., Propson, N. E., Hwang, S. H., Hammock, B. D., & Zheng, H. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.30.180984 · Cited by 6
Eben, T. J. (2024) · Cognizance Journal of Multidisciplinary Studies · doi:10.47760/cognizance.2024.v04i01.008 · Cited by 7
Valero-Rojas, J., Ramírez-Sánchez, C. A., Pacheco-Paternina, L., Valenzuela-Hormazábal, P., Saldívar‐González, F. I., Santana, P., González, J., Gutiérrez-Bunster, T., Valdés-Jiménez, A., & Ramírez, D. (2024) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.4c01481 · Cited by 8
Komura, T., & Nishikawa, Y. (2024) · Bioscience Biotechnology and Biochemistry · doi:10.1093/bbb/zbae172 · Cited by 4
Pregabalin Treatment does not Affect Amyloid Pathology in 5XFAD Mice
Sadleir, K. R., Popovoic, J., Zhu, W., Reidel, C. T., Do, H., Silverman, R. B., & Vassar, R. J. (2021) · Current Alzheimer Research · doi:10.2174/1567205018666210713125333 · Cited by 4
“Alzheimer’s disease is characterized by two hallmark pathologies, i.e., amyloid plaques and tau tangles [1, 2].”
Latli, B., Hrapchak, M. J., Frutos, R. P., Lee, H., & Song, J. J. (2023) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.4051 · Cited by 4
Metadata
- Authors
- Elmaleh, D. R., Farlow, M. R., Conti, P. S., Tompkins, R. G., Kundakovic, L., & Tanzi, R. E.
- Affiliations
- Massachusetts General Hospital (US)
- Indiana University School of Medicine (US)
- University of Southern California (US)
- Harvard University (US)
- AZTherapies (United States) (US)
- Corresponding author
- Elmaleh, David R.
- Venue
- Journal of Alzheimer’s Disease
- Publisher
- SAGE Publications
- Published
- 2019-08-27
- Volume
- 71
- Issue
- 3
- Pages
- 715-732
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- PMC
- PMC6839593
- OpenAlex
- W2971180542
- Cited by
- 129
- References
- 102
- Citations by year
- 2026: 5 · 2025: 12 · 2024: 22 · 2023: 20 · 2022: 16 · 2021: 29 · 2020: 24 · 2019: 1
- FWCI
- 2.06
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Alzheimer s Disease (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- IUScholarWorks (Indiana University) (acceptedVersion, cc-by)
- IUScholarWorks (Indiana University) (submittedVersion, cc-by)
- PMC
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, disease-modifying drugs
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Cognition, Humans, Middle Aged, Biomarkers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.